degarelix + enzalutamide + trametinib + dasatinib
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer
Trial Timeline
Sep 23, 2014 → Sep 30, 2026
NCT ID
NCT01990196About degarelix + enzalutamide + trametinib + dasatinib
degarelix + enzalutamide + trametinib + dasatinib is a phase 2 stage product being developed by Astellas Pharma for Prostate Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT01990196. Target conditions include Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Prostate Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01990196 | Phase 2 | Active |
Competing Products
20 competing products in Prostate Cancer